The China microarray market is projected to reach $910.4 million by 2031, at a CAGR of 8.4% from 2024 to 2031.
Following a comprehensive primary and secondary study and an in-depth analysis of the market scenario, this report provides the key drivers, constraints, challenges, and opportunities of the industry. This market is driven by increasing research applications of the microarray technology, growth in genomics & proteomics research, rising prevalence of cancers & genetic disorders, and growing R&D expenditures in the pharmaceutical & biotechnology industries.
Additionally, advancements in microarray technology and the growing adoption of personalized medicines provide significant growth opportunities for this market. However, the elevated costs of microarray compared to other genetic testing methods may restrain the growth of this market. Furthermore, the lack of sensitivity and accuracy in microarray poses a major challenge for the players operating in this market.
Among the products studied in this report, in 2024, the consumables segment is expected to account for the largest share of the China microarray market. Consumables encompass kits and additional items necessary for microarray applications, ensuring comprehensive and optimal sample preparation for accurate results and analysis. The large market share is driven by factors including streamlined workflows, reduced errors, cost efficiency, and minimized waste.
Among the applications studied in this report, in 2024, the drug discovery & development segment is expected to account for the largest share of the China microarray market. This large market share is attributed to factors such as elevated pharmaceutical R&D expenditures, a growing demand for novel drugs, increased government funding for drug discovery and development, and the rising adoption of microarray technology for identifying suitable therapeutic targets.
Among the end users studied in this report, in 2024, the pharmaceutical and biotechnology companies segment is expected to account for the largest share of the China microarray market. This large market share is driven by factors such as rising healthcare expenditures, increased investment and funding in pharmaceutical companies, advancements in research and development, and enhanced patient outcomes.
Some of the major players studied in this report are Sino Biological, Inc. (China), CapitalBio Technology Co., Ltd. (China), Arrayit Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), Revvity, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), and Qiagen N.V. (Netherlands), and RayBiotech Life, Inc. (U.S.).
Following a comprehensive primary and secondary study and an in-depth analysis of the market scenario, this report provides the key drivers, constraints, challenges, and opportunities of the industry. This market is driven by increasing research applications of the microarray technology, growth in genomics & proteomics research, rising prevalence of cancers & genetic disorders, and growing R&D expenditures in the pharmaceutical & biotechnology industries.
Additionally, advancements in microarray technology and the growing adoption of personalized medicines provide significant growth opportunities for this market. However, the elevated costs of microarray compared to other genetic testing methods may restrain the growth of this market. Furthermore, the lack of sensitivity and accuracy in microarray poses a major challenge for the players operating in this market.
Among the products studied in this report, in 2024, the consumables segment is expected to account for the largest share of the China microarray market. Consumables encompass kits and additional items necessary for microarray applications, ensuring comprehensive and optimal sample preparation for accurate results and analysis. The large market share is driven by factors including streamlined workflows, reduced errors, cost efficiency, and minimized waste.
Among the applications studied in this report, in 2024, the drug discovery & development segment is expected to account for the largest share of the China microarray market. This large market share is attributed to factors such as elevated pharmaceutical R&D expenditures, a growing demand for novel drugs, increased government funding for drug discovery and development, and the rising adoption of microarray technology for identifying suitable therapeutic targets.
Among the end users studied in this report, in 2024, the pharmaceutical and biotechnology companies segment is expected to account for the largest share of the China microarray market. This large market share is driven by factors such as rising healthcare expenditures, increased investment and funding in pharmaceutical companies, advancements in research and development, and enhanced patient outcomes.
Some of the major players studied in this report are Sino Biological, Inc. (China), CapitalBio Technology Co., Ltd. (China), Arrayit Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), Revvity, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), and Qiagen N.V. (Netherlands), and RayBiotech Life, Inc. (U.S.).
Table of Contents
1. Introduction
2. Research Methodology
4. Market Insights
5. China Microarray Market Assessment - By Product
6. China Microarray Market - By Application
7. China Microarray Market - By End User
8. Competition Analysis
9. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis)
Companies Mentioned
Some of the key companies profiled in this China Microarray Market report include:- Sino Biological Inc. (China)
- CapitalBio Technology Co. Ltd. (China)
- Arrayit Corporation (U.S.)
- Thermo Fisher Scientific Inc. U.S.
- Illumina Inc. U.S.
- Revvity Inc. U.S.
- Agilent Technologies Inc. U.S.
- Merck KGaA (Germany)
- Qiagen N.V. (Netherlands)
- RayBiotech Life Inc. U.S.
